Clinical Trials Logo

Vision clinical trials

View clinical trials related to Vision.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05533658 Completed - Cognitive Function Clinical Trials

The Effects of VisionPure™ on Indices of Vision Health and Cognitive Function

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

VisionPure™ is a softgel dietary supplement containing fish oil, lutein, zeaxanthin, and vitamin D. The intent of the VisionPure product is to assist in maintaining eye and cognitive health while helping to provide protection against blue throughout the day. In this pilot trial, approximately 16 participants will be recruited and randomly assigned to experimental and placebo conditions. Participants will consume 1 serving (2 softgels) per day of their respective study condition for 60 days. Prior to and following the 60 day supplementation period, participants will undergo a series of optometry and cognitive examinations to quantify eye health and cognitive function outcomes.

NCT ID: NCT04065061 Completed - fMRI Clinical Trials

Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations

Start date: May 22, 2015
Phase: N/A
Study type: Interventional

This study was designed as randomized double blind placebo study to investigate the efficacy of Erinacine A-enriched Hericium erinaceus mycelia for improvement of recognition, vision, and functional MRI alterations.

NCT ID: NCT02033200 Completed - Vision Clinical Trials

Safety Study Looking at the Effects of Stendra on Vision

Start date: January 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see if Stendra causes any changes in vision, eye pressure, pupil dilation, and color vision in healthy males.

NCT ID: NCT01138228 Completed - Vision Clinical Trials

Does the VTS1000 Infra Red Vein Imager Allow Better Identification of Veins Than Normal Eyesight?

VFvalidation
Start date: February 2010
Phase: N/A
Study type: Observational

VueTek has developed a head mounted device that will improve the viewing of superficial, subcutaneous vasculature, differentiating it with higher contrast from surrounding tissue. Video of the vasculature is displayed to the user in a portable headset. The headset and display combination facilitates both visualization in the display and an open field of view directly to the subject's anatomy and practitioner's surroundings. The goal is to provide a non-diagnostic, enhanced visual aide that is used alongside standard visual and tactile methodology. The primary and secondary objectives of this validation are as follows: 1. Primary Objective: To demonstrate that the VTS1000 affords visualization of superficial, subcutaneous vascular structures, when compared to the naked eye. 2. Secondary Objective: To demonstrate that the VTS1000 enhances visualization of superficial, subcutaneous vascular structures over the naked eye. Validation Ancillary Endpoints 1. To gather data to demonstrate that the VTS1000 is portable, affords conventional vascular access methods, and provides flexibility, fit and balance during use.

NCT ID: NCT01057966 Completed - Vision Clinical Trials

Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets

Start date: February 2010
Phase: Phase 4
Study type: Interventional

This study is a comparison of the bioavailability of nutrients contained in softgel capsules vs tablets.

NCT ID: NCT00713076 Completed - Vision Clinical Trials

Wettability of Contact Lenses With a Multi-Purpose Solution

Start date: October 2007
Phase: N/A
Study type: Interventional

Measure wettability of hydrogel and silicone hydrogel contact lenses presoaked in a Multi-Purpose Solution.

NCT ID: NCT00591110 Completed - Eye Disease Clinical Trials

Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program

inCharge
Start date: June 2008
Phase: N/A
Study type: Interventional

The study design is a randomized intervention evaluation. Ten senior centers in predominately African American communities in the Birmingham, Alabama will be selected as sites for the educational intervention. Five centers will be randomly assigned to receive an educational intervention communicating practical information about vision, eye conditions and eye care as pertinent to the older African American population. The other five centers will serve as social-contact controls, where participants will receive an engaging information session on a non-health related topic. The primary outcome of interest is the change in percentage of persons receiving comprehensive eye care from pre- to post- intervention. The secondary outcomes are the process outcomes of improvement in knowledge, attitudes, and values about vision, eye conditions, and eye care.

NCT ID: NCT00357409 Completed - Vision Clinical Trials

GABA Levels in the Brains of Blind People

Start date: February 11, 2002
Phase: N/A
Study type: Observational

In blind individuals, the occipital cortex becomes capable of processing tactile and auditory information, a phenomenon described as crossmodal plasticity. GABA is the major inhibitory neurotransmitter in the brain and a possible candidate to mediate this form of human plasticity. We intend to use magnetic resonance spectroscopy (MRS) to measure GABA and hypothesize that GABA levels in the occipital cortex of blind humans will be lower than in sighted controls. Such decrease could possibly mediate compensatory changes in the occipital cortex of the blind. Objective Early blind subjects exhibit better tactile acuity than late blinds or sighted individuals. The purpose of the study is the determine GABA levels in the human occipital cortex after long-term light deprivation (blindness). Study Population Our experiments will make use of early blind, late blind, and sighted control subjects. Design Subject will be identified and will receive clinical and neurological examinations at the NIH. MRS studies will be performed at NIH MRI Center with 3Tesla Magnet. Each subject head will be positioned in an adjustable holder (designed for minimal motion and maximal comfort) such that a flat coil lay just below the occipital cortex. The sequence has been described before [33]. The individuals who perform the data analysis will be blind to the purpose of the experiments. Outcome measures The concentration of GABA from the 14 ml voxel over the visual cortex will be measured. Edited proton spectrum of GABA will be compared with the edited sub spectrum of creatine for a concentration reference.